Phase 3 study of IMMU-130 in patients with advanced, refractory, colorectal cancer
Latest Information Update: 20 Jan 2017
Price :
$35 *
At a glance
- Drugs Labetuzumab govitecan (Primary)
- Indications Colorectal cancer
- Focus Registrational; Therapeutic Use
- 20 Jan 2017 New trial record